Danazol
Ovarian Cysts
Centre for Endocrinology and Reproductive Medicine, ItalySmall moleculePhase 4 / ApprovedDormant
BB
69/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 54/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Ovarian Cysts cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Letrozole Wake Forest University Health Sciences | Phase 4 | BB |
Cetrotide Zagazig University | Phase 4 | BB |
Ganirelix Assaf-Harofeh Medical Center | Phase 4 | BB |
ROPIVACAINE San Gerardo Hospital | Phase 3 | BB |
Adhexil OMRIX Biopharmaceuticals | Phase 3 | B |
View all 13 →
Same molecule, other indications
Danazol is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →